first review of bisoprolol fumarate tablets of Zhongguancun Subsidiary Company
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
Looking for chemical products? Let suppliers reach out to you!
Exploring the way of generic drug
2026-07-06
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Market Analysis - Monthly Report - May, 2020 - Tiamulin Fumarate
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
Recommend Reading
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Premium Global Chemical Sourcing Requests (15-19 Nov 2025)
-
A $25 Billion “Mega Merger” Is Born: How the AkzoNobel × Axalta Deal Rewrites Global Coatings Power
-
Evonik Restructures Strategic R&D and Aims to Move Projects into Application Within Five Years
-
BASF Opens Up PolyTHF® Technology: A Quiet but Powerful Shake-Up in the Global Fibers Game
-
On January 15, China's titanium dioxide market remains firm and upward